10294 Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices 

Medical Center. The meeting will be 

held on Friday, March 19, 2010, at the 

National Institutes of Health, Building 

31, 31 Center Drive, Floor 6C, Room 6, 

Bethesda, MD 20892, from 

approximately 8:30 a.m. to 2 p.m. 

This meeting is the second in a series 

of public meetings with the National 

Research Council to review the ongoing 

supplementary risk assessment study. It 

was originally scheduled to take place 

on February 12, 2010, but had to be 

postponed due to extreme weather 

conditions on the East Coast. 

Signup for public comment will begin 

at approximately 8 a.m. In the event that 

time does not allow for all those 

interested in presenting oral comments, 

anyone may file written comments 

using the following address below. 

An agenda and slides for the meeting 

may be obtained prior to the meeting by 

connecting to http:// 

nihblueribbonpanel-bumcneidl.od.nih.gov/. For additional 

information concerning this meeting, 

please contact Ms. Laurie Lewallen, 

Advisory Committee Coordinator, Office 

of Biotechnology Activities, Office of 

Science Policy, Office of the Director, 

National Institutes of Health, 6705 

Rockledge Drive, Room 750, Bethesda, 

MD 20892–7985; telephone 301–496– 

9838; e-mail lewallenl@od.nih.gov. 

Dated: March 1, 2010. 

Amy P. Patterson, 

Director, Office of Biotechnology Activities, 

National Institutes of Health. 

[FR Doc. 2010–4724 Filed 3–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, NIDCD. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

NATIONAL INSTITUTE ON DEAFNESS 

AND OTHER COMMUNICATION 

DISORDERS, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, NIDCD. 

Date: March 26, 2010. 

Open: 7:30 a.m. to 8 a.m. 

Agenda: Reports from institute staff. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Room F1/ 

F2, Bethesda, MD 20892. 

Closed: 8 a.m. to 4:30 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Room F1/ 

F2, Bethesda, MD 20892. 

Contact Person: Andrew J. Griffith, Ph.D., 

MD., Director, Division of Intramural 

Research, National Institute on Deafness and 

Other Communication Disorders, 5 Research 

Court, Room 1A13, Rockville, MD 20850, 

301–496–1960, griffita@nidcd.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: March 1, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–4767 Filed 3–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0054] 

Strengthening the Center for Devices 

and Radiological Health’s 510(k) 

Review Process; Public Meeting; 

Extension of Comment Period 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; extension of comment 

period. 

SUMMARY: The Food and Drug 

Administration (FDA) is extending to 

March 19, 2010, the comment period for 

the notice that appeared in the Federal 

Register of Wednesday, January 27, 

2010 (75 FR 4402). In the notice, FDA 

requested comments on a number of 

identified challenges associated with 

the 510(k) process. The agency is taking 

this action to allow interested persons 

additional time to submit comments. 

DATES: Submit written or electronic 

comments and information by March 

19, 2010. 

ADDRESSES: Submit written comments 

or information to the Division of 

Dockets Management (HFA–305), Food 

and Drug Administration, 5630 Fishers 

Lane, rm. 1061, Rockville, MD 20852. 

Submit electronic comments or 

information to http:// 

www.regulations.gov. Identify 

comments with the docket number 

found in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

James Swink, Center for Devices and 

Radiological Health, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 66, rm. 1609, Silver Spring, 

MD 20993, 301–796–6313, e-mail: 

james.swink@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

In the Federal Register of January 27, 

2010 (75 FR 4402), FDA published a 

notice announcing a public meeting on 

February 18, 2010, and the opening of 

a public docket to receive comments on 

key challenges related to the premarket 

notification (or 510(k)) process for the 

review of medical devices. Specific 

questions for comment were listed and 

interested persons were invited to 

submit comments by March 5, 2010. At 

this time, the agency is extending the 

comment period until March 19, 2010, 

to continue to receive public comments. 

Comments submitted to the docket will 

assist in identifying actions that the 

Center for Devices and Radiological 

Health can consider taking to strengthen 

the 510(k) process. 

II. Submission of Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic 

comments regarding this document. 

Submit a single copy of electronic 

comments or two paper copies of any 

mailed comments, except that 

individuals may submit one paper copy. 

All comments submitted to the public 

docket are public information and may 

be posted to FDA’s Web site at http:// 

www.fda.gov for public viewing. 

Comments are to be identified with the 

docket number found in brackets in the 

heading of this document. In addition, 


erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 75, No. 43 / Friday, March 5, 2010 / Notices 10295 

when responding to specific questions 

as outlined in the Federal Register of 

January 27, 2010, please identify the 

question you are addressing. Received 

comments may be seen in the Division 

of Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday. 

Dated: March 1, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–4662 Filed 3–4–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; The Early 

Detection Research Network: Biomarker 

Reference Laboratories. 

Date: March 23, 2010. 

Time: 8 a.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Legacy Hotel and Meeting Center, 

1775 Rockville Pike, Rockville, MD 20852. 

Contact Person: Gerald G. Lovinger, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8101, 

Bethesda, MD 20892–8329, 301/496–7987, 

lovingeg@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Pharmacodynamic Assays. 

Date: March 23, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: Legacy Hotel and Meeting Center, 

1775 Rockville Pike, Rockville, MD 20852. 

Contact Person: Thomas M. Vollberg, PhD, 

Scientific Review Officer, Special Review 

and Logistics Branch, Division of Extramural 

Activities, National Cancer Institute, 6116 

Executive Boulevard, Room 7142, Bethesda, 

MD 20892, 301–594–9582, 

vollbert@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI– 

CNP(U54) Review. 

Date: April 7–9, 2010. 

Time: 5 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington, DC/Rockville 

Hotel, 1750 Rockville Pike, Rockville, MD 

20852. 

Contact Person: Bratin K. Saha, PhD, 

Scientific Review Officer, Program 

Coordination and Referral Branch, Division 

of Extramural Activities, National Cancer 

Institute, NIH, 6116 Executive Boulevard, 

Room 8041, Bethesda, MD 20892, (301) 402– 

0371, sahab@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 26, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–4727 Filed 3–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Member 

Conflict: Topics in Aging, Cellular and 

Developmental Biology. 

Date: March 23, 2010. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Sherry L. Dupere, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5136, 

MSC 7843, Bethesda, MD 20892, (301) 435– 

1021, duperes@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel Member 

Conflicts: Arthritis, Connective Tissue, and 

Skin. 

Date: March 30, 2010. 

Time: 1:30 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Jean D. Sipe, PhD., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4106, 

MSC 7814, Bethesda, MD 20892, 301/435– 

1743, sipej@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: March 1, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–4726 Filed 3–4–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Viral Immunity. 

Date: March 31, 2010. 

Time: 12:30 p.m. to 4:30 p.m. 


erowe on DSK5CLS3C1PROD with NOTICES